What is Bicycle Therapeutics plc (BCYC)?

Bicycle Therapeutics plc (BCYC) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of BCYC?

The current price of BCYC is $3.78. Prices are updated in real time on Stocks360.

What is BCYC's price-to-earnings (PE) ratio?

BCYC's trailing twelve-month PE ratio is -1.38, based on current price and earnings per share data available on Stocks360.

What is BCYC's market capitalization?

BCYC's market capitalization is $263,897,461.00, placing it in the small-cap tier.

Bicycle Therapeutics plc (BCYC)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$3.78

Market Cap

$263.90M

PE (TTM)

-1.38

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.68

Day Range

$3.65 – $3.85

52-wk Range

$3.33 – $9.08

Avg Volume

N/A

Volume

486.23K

Bicycle Therapeutics plc (BCYC) is a publicly traded company in the Healthcare sector. Latest price: $3.78. Market cap $263.90M. Trailing PE -1.38. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-28 · $8.22 2026-10-27 · $3.78 (-54.01%)

Earnings

Most Recent

Jul 30, 2026

EPS $-0.72 vs est. $-0.56

Missed by $0.16

Next Earnings

Oct 29, 2026

EPS estimate $-0.40

Proprietary Signals

Signal snapshot temporarily unavailable.

About Bicycle Therapeutics plc

Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate (BTC) that is undergoing Phase I/IIa clinical trials. This candidate is engineered to target tumors specifically expressing Membrane Type 1 matrix metalloprotease. Other oncology assets in their pipeline include BT5528, also a BTC in Phase I/II studies, which targets EphA2, and BT8009, currently in Phase I/II clinical development, designed to target Nectin-4. Beyond cancer, Bicycle Therapeutics is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase II clinical trials for the treatment of diabetic macular edema. Their portfolio also includes Bicycle tumor-targeted immune cell agonists (TICAs) such as BT7480, which targets Nectin-4, and BT7455, an EphA2/CD137 TICA presently in preclinical development. The company actively fosters collaborations with various biopharmaceutical entities and organizations, broadening its development efforts into therapeuti…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-1.38×
P/S (TTM)	4.31×
P/B	0.52×
P/FCF (TTM)	-1.28×
EV / EBITDA	1.27×
EV / Sales	-3.80×
Earnings Yield	-72.16%
Free Cash Flow Yield	-77.91%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$232.47M
Net Income (TTM)	-$190.44M
Free Cash Flow (TTM)	-$205.40M
Net Debt	-$496.37M
Working Capital	$527.60M
Gross Margin	100.00%
Operating Margin	-343.69%
Net Margin	-311.11%
Return on Equity	-33.22%
Return on Invested Capital	-37.63%